ProQR Therapeutics N.V. (PRQR) PT Lowered to $23 at JMP Securities, After Company Reports Findings From Interim Analysis In Phase 1/2 Trial Of QR-421a
Tweet Send to a Friend
JMP Securities analyst Liisa A. Bayko ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
